Non-Small Cell Lung Cancer Videos

Tejas Patil, MD, University of Colorado Cancer Center

Videos

Utilizing Clinical Pathways in the Treatment of Patients With ALK-Positive NSCLC

04/14/2023

Tejas Patil, MD, University of Colorado Cancer Center, discusses recent developments in the treatment landscape for patients with ALK-positive NSCLC and how clinical pathways can help standardize the treatment practices for these patients.

Tejas Patil, MD, University of...

04/14/2023

Journal of Clinical Pathways

Videos

Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape

11/03/2022

Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.

Janet Espirito, PharmD,...

11/03/2022

Journal of Clinical Pathways

Videos

Identifying Predictors of Biomarker Testing in Metastatic Non-Small Cell Lung Cancer

07/05/2022

Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.

Nicholas Robert, MD, discusses...

07/05/2022

Journal of Clinical Pathways

Videos

Real-World Testing and Treatment Patterns in Advanced NSCLC

10/18/2021

Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.

Geoffrey Oxnard, MD, compares...

10/18/2021

Journal of Clinical Pathways

Videos

Cost-Effectiveness of Adjuvant Osimertinib for EGFR-Mutant NSCLC

07/01/2021

Christopher Lemmon, MD, discusses results from a study on the cost-effectiveness of adjuvant osimertinib in resected EGFR mutant NSCLC patients, finding that it may have the potential to be cost-effective, given the right financial...

Christopher Lemmon, MD,...

07/01/2021

Journal of Clinical Pathways

Videos

Cost-Effectiveness of Adjunctive Osimertinib for EGFR-Positive NSCLC

06/10/2021

Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.

Briana Choi, PharmD, discusses...

06/10/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Non-Small Cell Lung Cancer Videos

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products